Friday 6 November 2026 Export NDRA’s income statement to Excel — free account

ENDRA Life Sciences Inc.

NDRA Healthcare Diagnostics & Research

EPS: +107.0%
Free cash flow: +15.0%

Quarter to June 2026, against a year earlier

Operating cash flow growth 3 yrs

4.65 0.29 −5.87%

Follow NDRA

Alert me

Market cap: $7.5M
P/E: 0.0×
Fwd P/E: −0.7×
Dividend yield: —
F-score: 5/9
Altman Z: −4.33
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 46.37%

Capital & Financial Ratios $m

Size

Market Cap 7.51

Revenue ttm 0.36

Net income ttm (5.92)

Free cash flow ttm (7.84)

Net debt Q (5.54)

Valuation

P/E 0.00

Forward P/E (0.70)

Price / sales 17.21

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.98

Financial health

Current ratio Q 7.10

Debt / equity Q 0.00

Interest coverage Q 0.54

Growth

Revenue growth Q −98.80%

Operating income growth Q −14.00%

EPS, this year +60.36%

EPS, next year A +14.12%

Revenue, next year A −100.00%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 32.10%

10-year low 10-year high

P/B against its own 10 years 13.41%

10-year low 10-year high

EV/Sales against its own 10 years 3.56%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	3	1	6
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	3	3	1	6

	2023	2024	2025	Q'26
Payables	1	1	1	1
ST’ Debt	0	—	—	—
Other	—	—	—	—
	1	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(20.62%)	(32.05%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.84 Actual −0.63

−2.15 −1.72 −1.29 −0.86 −0.43

Q3 FY25 Beat +0.20

Q4 FY25 Miss −0.44

Q1 FY26 Miss −0.43

Q2 FY26 Beat +0.21

Q3 FY26 — Nov 13

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q3 FY25	−1.95	−1.75	Beat by 0.20
Q4 FY25	−1.23	−1.67	Miss by 0.44
Q1 FY26	−1.23	−1.66	Miss by 0.43
Q2 FY26	−0.84	−0.63	Beat by 0.21
Q3 FY26	−0.84	—	Reports 13 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.09)	0.06	—	—	—
’25	(1.86)	(1.71)	(2.10)	(2.85)	(8.93)
’24	(454.54)	(139.86)	(9.54)	(20.78)	(56.94)
’23	(1.63k)	(751.75)	(699.30)	(297.20)	(2.76k)
’22	(2.45k)	(2.10k)	(1.75k)	(1.82k)	(7.97k)
’21	(2.10k)	(2.80k)	(2.10k)	(2.45k)	(9.79k)
’20	(10.14k)	(6.99k)	(5.24k)	(3.50k)	(22.03k)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’18	0	—	—	—	0
’17	—	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	(1)	(2)	(5)
’24	(2)	(2)	(2)	(2)	(7)
’23	(3)	(2)	(3)	(2)	(10)
’22	(3)	(3)	(3)	(3)	(13)
’21	(3)	(3)	(3)	(3)	(11)
’20	(3)	(3)	(2)	(2)	(11)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(1)	—	—	—
’25	(1)	(1)	(1)	(5)	(8)
’24	(2)	(2)	(2)	(2)	(7)
’23	(3)	(2)	(3)	(2)	(10)
’22	(3)	(3)	(3)	(3)	(13)
’21	(3)	(3)	(3)	(3)	(11)
’20	(3)	(3)	(2)	(2)	(11)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	1	0	0	—	—	—	—	—	—	—	0		(89.0%)	0	0	—	0.0%
	Gross margin, %	54.25	50.85	100.00	0.00	0.00	0.00	0.00	—	—	—	0.00		(54.2) pt	Powerpack ENDRA Life Sciences Inc.’s next three years, line by line Analysts expect revenue to grow 0.0% a year to 2028 — faster than the −89.0% of the last 2 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(3)	(5)	(10)	(13)	(12)	(11)	(13)	(10)	(12)	(7)	(6)		+10.9%
	EBT margin, %	(538.29)	(1,529.29)	(158,004.84)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		+538.3 pt
	Net income	(3)	(5)	(10)	(13)	(12)	(11)	(13)	(10)	(12)	(7)	(6)		+10.9%
Per share, $
Per share, $	Revenue	0.00	4,463.62	48.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(134,219.70)	(68,261.40)	(76,110.72)	(81,818.18)	(22,027.97)	(9,790.21)	(7,972.03)	(2,762.24)	(56.94)	(8.93)	(5.92)		(65.7%)
	Cash flow	0.00	(41,905.44)	(59,843.51)	(42,944.50)	(21,493.20)	(9,268.67)	(7,511.41)	(2,652.44)	(36.64)	(6.59)	(3.64)		n/m
	Capex	0.00	(100.29)	(776.94)	(218.00)	(150.60)	(37.50)	(119.18)	(6.86)	(0.06)	(3.83)	(2.28)		n/m
	Free cash flow	0.00	(42,005.73)	(60,620.45)	(43,162.50)	(21,643.80)	(9,306.17)	(7,630.59)	(2,659.31)	(36.70)	(10.42)	(5.92)		n/m
	Book value	0.00	66,973.30	48,544.53	23,803.50	14,338.60	8,986.92	4,237.94	1,571.94	12.68	2.87	4.77		n/m
	Shares, m	0	0	0	0	0	0	0	0	0	1	1		n/m
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	—	—	—	—	—	—	—	0.00		0.0
	P/S	0.00	19.97	14.67	—	—	—	—	—	—	—	17.21		11.5
	P/B	1.75	3.28	0.84	—	—	—	—	—	—	—	0.98		2.0
	EV/Sales	0.00	13.51	(3.41)	—	—	—	—	—	—	—	1.88		3.4
	EV/FCF	(3.19)	(3.54)	0.16	—	—	—	—	—	—	—	(0.09)		(2.2)
Cash, $m
Cash, $m	Operating cash flow	(1)	(3)	(8)	(9)	(11)	(11)	(13)	(10)	(7)	(5)	(5)		+16.5%
	Capex	—	0	0	0	0	0	0	0	0	(3)	(3)		+110.3%
	Free cash flow	(1)	(3)	(8)	(9)	(11)	(11)	(13)	(10)	(7)	(8)	(8)		+22.5%
Balance, $m
Balance, $m	Working capital	(1)	5	6	4	7	11	6	2	3	0	5		n/m
	Net debt	1	(6)	(6)	(5)	(7)	(9)	(5)	(3)	(3)	(1)	(6)		n/m
	Shareholders’ equity	(1)	5	6	5	7	11	7	6	3	2	6		n/m
Returns, %
Returns, %	ROA	(83.92)	(162.58)	(146.80)	(243.43)	(152.07)	(104.92)	(119.01)	(125.53)	(205.38)	(169.21)	(110.08)		(85.3) pt
	ROIC	0.00	0.00	0.00	0.00	(2,021.57)	(484.39)	(350.85)	(230.43)	0.00	(240.50)	(539.89)		(240.5) pt
	ROE	(126.68)	(245.43)	(170.02)	(318.39)	(203.20)	(126.46)	(146.53)	(156.42)	(280.02)	(291.56)	(152.04)		(164.9) pt
People
People	Employees	8	13	11	15	18	22	21	21	21	11	—		+3.6%
	Revenue/emp, $m	0.06	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2018 · latest quarter Mar 2018 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MDXH MDxHealth SA	$14.4M	— (loss-making)	— (loss-making)	+12.01% (above 0%: growing)	n/m	−200.20% (below 0%: shrinking)	65.75%	(18.74%)	Compare
NDRA ENDRA Life Sciences Inc.	$7.5M	— (loss-making)	— (loss-making)	−98.80% (below 0%: shrinking)	n/m	+15.04% (above 0%: growing)	0.00%	0.00%
TTOO T2 Biosystems, Inc.	$6.5M	— (loss-making)	— (loss-making)	+34.85% (above 0%: growing)	n/m	+53.36% (above 0%: growing)	(106.60%)	(511.89%)	Compare
XWEL XWELL, Inc.	$6.1M	— (loss-making)	— (loss-making)	−7.08% (below 0%: shrinking)	n/m	−43.02% (below 0%: shrinking)	41.26%	(29.45%)	Compare
BIAF bioAffinity Technologies, Inc.	$3.3M	— (loss-making)	— (loss-making)	+18.99% (above 0%: growing)	n/m	−23.69% (below 0%: shrinking)	27.98%	(220.77%)	Compare
DMTKQ DermTech, Inc.	$3.3M	— (loss-making)	— (loss-making)	+10.58% (above 0%: growing)	n/m	+24.87% (above 0%: growing)	18.54%	(533.37%)	Compare
ADVB Advanced Biomed Inc.	$3.1M	0.3×	—	—	n/m	−101.33% (below 0%: shrinking)	—	0.00%	Compare
AWHL Aspira Women's Health Inc.	$2.4M	— (loss-making)	— (loss-making)	−14.89% (below 0%: shrinking)	n/m	−24.57% (below 0%: shrinking)	55.28%	(89.69%)	Compare
ISPC iSpecimen Inc.	$2.0M	— (loss-making)	— (loss-making)	−78.70% (below 0%: shrinking)	n/m	−257.73% (below 0%: shrinking)	45.23%	(897.30%)	Compare
Median of peers	$3.3M	—	—	+10.58%	—	−33.80%	41.26%	(155.23%)

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 28 October 2025

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2024	215.19k	194.78k	30.00

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

ENDRA Life Sciences Inc. (NDRA) Latest News

17 Aug

Impact 3 · 8:00 AM

ENDRA Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

25 Jun

Impact 5 · 9:51 AM · Business Wire

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

Impact 4 · 9:30 AM

ASP Isotopes Announces Proposed Merger of Noble Africa with ENDRA Life Sciences and Approximately $50 Million Concurrent Private Placement Financing

Impact 3 · 12:11 PM · Stocktwits

ASP Isotopes To Merge Noble Africa With A Unit Of ENDRA – A Look At The Key Contours Of The Deal

18 May

Impact 4 · 8:00 AM · Business Wire

ENDRA Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update

14 May

Impact 4 · 8:00 AM · Business Wire

ENDRA Life Sciences Reports Multi-Site Validation of TAEUS® Liver Device Demonstrating MRI-like Accuracy and Reproducibility

31 Mar

Impact 4 · 4:05 PM · Business Wire

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Impact 4 · 8:05 AM · Business Wire

ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

Impact 3 · 8:00 AM

ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

25 Mar

Impact 4 · 8:00 AM · Business Wire

ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

3 Mar

Impact 4 · 10:15 AM · Zacks

NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision

26 Feb

Impact 4 · 8:00 AM · Business WirePharmaceutical TechnologyZacksMarketBeatBioPharma DiveMarketBeat

ENDRA’s TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care

4 Dec

Impact 4 · 8:00 AM · Business Wire

ENDRA’s TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use

20 Nov

Impact 4 · 8:00 AM

ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker

17 Nov

Impact 4 · 8:00 AM · Business Wire

ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results

14 Nov

Impact 3 · 9:25 AM · TipRanks

Endra Life Sciences commences staking of HYPE digital asset holdings

14 Aug

Impact 3 · 4:05 PM · Business Wire

ENDRA Life Sciences Provides a Business Update and Reports Second Quarter 2025 Financial Results

16 Jun

Impact 4 · 8:00 AM · Business Wire

ENDRA’s Ongoing Multisite Pilot Study Reveals Important Enhancements to Boost TAEUS Liver Accuracy and Repeatability Against MRI Gold Standard

15 May

Impact 3 · 4:05 PM

ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

28 Jan

Impact 4 · 12:00 PM · Zacks

What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock

22 Nov

Impact 3 · 8:00 AM · Business Wire

ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

15 Nov

Impact 4 · 9:24 AM · Business Wire

ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update

12 Nov

Impact 4 · 8:00 AM

Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024

6 Nov

Impact 4 · 8:00 AM · Business Wire

ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent

22 Oct

Impact 4 · 8:00 AM · Business Wire

ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany

22 Aug

Impact 4 · 4:14 PM · Business Wire

ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update

16 Aug

Impact 3 · 8:00 AM · Business Wire

ENDRA Life Sciences Announces Reverse Stock Split

13 Aug

Impact 4 · 8:00 AM · Business Wire

ENDRA Life Sciences Announces Leadership Changes

7 Aug

Impact 3 · 8:00 AM · Business Wire

ENDRA Life Sciences to Report Second Quarter 2024 Financial Results on August 14

4 Jun

Impact 4 · 9:21 AM · Business Wire

ENDRA Life Sciences Announces Pricing of $8.0 Million Public Offering

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

ENDRA Life Sciences Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 28 October 2025

Chief executive’s pay

ENDRA Life Sciences Inc. (NDRA) Latest News

17 Aug

25 Jun

18 May

14 May

31 Mar

25 Mar

3 Mar

26 Feb

4 Dec

20 Nov

17 Nov

14 Nov

14 Aug

16 Jun

15 May

28 Jan

22 Nov

15 Nov

12 Nov

6 Nov

22 Oct

22 Aug

16 Aug

13 Aug

7 Aug

4 Jun

Stockrow Weekly